Navigation Links
ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
Date:7/29/2009

n statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. Forward looking statements in this press release include our financial guidance for 2009, and statements regarding our clinical development programs, the effectiveness of our Vancocin and Cinryze sales efforts, our estimates of future tax rates, or our ability to execute a successful launch of Cinryze, our ability to conduct future studies with maribavir, and the timing and potential outcomes of the review of our regulatory submission related to an acute treatment indication for Cinryze.

We plan to remain vigorous in our opposition to any bioequivalence approach considered for use in approving generic formulations of Vancocin that does not require rigorous scientific methods to demonstrate safety and efficacy consistent with good medicine and science. The FDA will convene a meeting of its Advisory Committee for Pharmaceutical Science and Clinical Pharmacology to discuss bioequivalence recommendations for oral vancomycin hydrochloride capsule drug products. The meeting is scheduled for August 4, 2009. We have submitted briefing materials to the Advisory Committee for its consideration on the issues presented by OGD's bioequivalence recommendation, and we expect to present these issues at the meeting. There can be no assurance that the FDA will agree with the positions stated in our Vancocin related submissions or that our efforts to oppose the FDA's December 2008 bioequivalence guidance for Vancocin will be successful. We cannot predict the timeframe in which the FDA will make a decision regarding either our citizen petition for Vancocin or the approval of generic versions of Vancocin. If we are unable to change the recommendation set forth by the FDA in December 2008, the threat of generic competition will be high. The entry of competing
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
2. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
3. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
4. ViroPharma to Present at Two May Healthcare Conferences
5. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
6. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
7. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
8. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
9. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. ViroPharma Provides Update on Vancocin(R)
11. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... PA (PRWEB) September 20, 2014 "As a ... in their tanks," said an inventor from Tamaqua, Pa. "The ... mounted on the backs of their chairs. My invention enables ... developed the Kam Oxygen Sensor to make it easier to ... that the user knows when the tank is low. It ...
(Date:9/20/2014)... Earlier this week, Home Depot revealed that up ... credit card information pilfered by hackers, surpassing the 40 million ... articles like this one published by Bloomberg on ... , “Most people tend to focus on how many ... to score a game,” says Joe Caruso, founder and CEO/CTO ...
(Date:9/20/2014)... September 20, 2014 Final Cut Pro ... the release of the Information theme for FCPX filmmakers. , ... to describe the Information theme,” says Christina Austin, CEO of ... look so professional.” , Information features easy to use controls ... of the environment. Change the background color, color of each ...
(Date:9/20/2014)... “Motherhood is a wonderful gift and a huge responsibility,” ... article , “We know that you want to care for ... want to do as well.” , The article explains to ... their Family Physicians who practice obstetrics while pregnant, during delivery, ... To learn more about Community Health Center of Snohomish County ...
(Date:9/19/2014)... 20, 2014 Nearly 780 Risperdal lawsuits ... Pleas where a meeting took place to discuss the ... in the court’s mass tort program. Attorneys for ... past week at the Complex Litigation Center in Philadelphia’s ... pretrial proceedings. The Risperdal lawsuits filed against Johnson & ...
Breaking Medicine News(10 mins):Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:Newest Article from Community Health Center of Snohomish County Highlights The Importance of Proper Health Care for Expectant Mothers 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4
... claim up to 3 million lives a year. WHO released ... of March. The report says most of those who die ... in the developing world are particularly at risk for water-borne ... drinking contaminated water and 90% of those deaths are among ...
... always raises many uncomfortable questions and more troubling answers is ... ethical issue and has kindled a lot of heated arguments ... victims suffer the most when it comes to drug testing ... on unsuspecting victims in the name of conducting a study.,A ...
... toddler, aged 13 months from Edmonton, Alberta, wandered into a ... in sub zero temperatures. She was frozen stiff and her ... the hospital, doctors declared her clinically dead, but lo and ... miraculous recovery. Read on to know more. , The temperature ...
... conducted by Dr. Michael Brent, an associate professor of ... gives us an insight into the way children understand ... were presented at the annual meeting of the American ... years the ability of children to pick up language ...
... ad with a macabre sense of humour. It stirred up ... over the United States. Levis Strauss officially announced that the ... complaints from many who felt that they did not enjoy ... shows an unconscious man falling from a carousel horse. A ...
... doctors are being stretched to their limits working on cases ... in candlelight when the power fails, but the work goes ... open verandahs. On Jan 27th nearly 1500 patients were operated ... rays. ,The worst quake in Indian history has ...
Cached Medicine News:
(Date:9/19/2014)... N.J. , Sept. 19, 2014 Merck (NYSE: ... States and Canada , is teaming ... Desafiando La Diabetes: Logra Tus Metas , an educational program encouraging ... blood sugar -- a key treatment goal to help reduce the ... States are at a higher risk for developing type ...
(Date:9/19/2014)... R.I. , Sept. 19, 2014 Larry ... CVS ), will speak before the National Press ... will discuss the company,s recent move to stop selling tobacco ... shape the future of health. "Dramatic changes in ... health care providers and government," Merlo has said. "CVS Health ...
(Date:9/19/2014)... -- BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical ... ® in the U.S. and XIAPEX ® in ... , will present a corporate overview at the 21 st ... The presentation will take place on Friday, September ... Hotel in New York, NY . A ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2
... , , LACHEN, Switzerland and HOBOKEN, N.J., ... m a AG is leading an ... therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, ... from a human cell line, could dramatically impact the treatment of an ...
... , , , ... AMGN ) today announced that in a large, randomized, double-blind, placebo-controlled, ... requiring dialysis), anemia and type-2 diabetes (the T rial to ... T herapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin ...
Cached Medicine Technology:Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies 2Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies 3Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies 4Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies 5Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 2Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 3Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 4Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 5Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 6Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 7Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 8
... is synthesized in the parafollicular C-cells of ... secretory granules. The major action of calcitonin ... inhibiting osteoclast activity, resulting in decreased mobilization ... is most evident in conditions associated with ...
... test provides a method for the lay user ... is comprised of a plastic probe with pH ... a package insert. The plastic probe is in ... is indicated for measuring vaginal pH for the ...
... The Rapidlab 1200's speed and accuracy ... decisions in a timely manner - ... value, especially patients. In fact, the ... parameters in just one minute. Its ...
Dornier Holmium Laser for Urological Procedures...
Medicine Products: